Belite Bio Inc. ADS/$BLTE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Belite Bio Inc. ADS
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Ticker
$BLTE
Sector
Primary listing
Employees
41
Headquarters
Website
BLTE Metrics
BasicAdvanced
$6.1bn
-
-$2.31
-1.22
-
Price and volume
Market cap
$6.1bn
Beta
-1.22
52-week high
$200.00
52-week low
$56.10
Average daily volume
142k
Financial strength
Current ratio
50.017
Quick ratio
49.901
Long term debt to equity
0.024
Total debt to equity
0.056
Interest coverage (TTM)
-42,104.00%
Profitability
EBITDA (TTM)
-84.024
Management effectiveness
Return on assets (TTM)
-11.29%
Return on equity (TTM)
-16.94%
Valuation
Price to book
7.91
Price to tangible book (TTM)
7.91
Price to free cash flow (TTM)
-139.735
Free cash flow yield (TTM)
-0.72%
Free cash flow per share (TTM)
-1.108
Growth
Earnings per share change (TTM)
95.52%
3-year earnings per share growth (CAGR)
54.04%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Belite Bio Inc. ADS stock?
Belite Bio Inc. ADS (BLTE) has a market cap of $6.1B as of May 02, 2026.
What is the P/E ratio for Belite Bio Inc. ADS stock?
The price to earnings (P/E) ratio for Belite Bio Inc. ADS (BLTE) stock is 0 as of May 02, 2026.
Does Belite Bio Inc. ADS stock pay dividends?
No, Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders as of May 02, 2026.
When is the next Belite Bio Inc. ADS dividend payment date?
Belite Bio Inc. ADS (BLTE) stock does not pay dividends to its shareholders.
What is the beta indicator for Belite Bio Inc. ADS?
Belite Bio Inc. ADS (BLTE) has a beta rating of -1.22. This means that it has an inverse relation to market volatility.